Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer-Reference-Cited by-同舟云学术

Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer

Published:2017-08 Issue: Volume:81 Page:228-236
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Armstrong Andrew J.,Halabi Susan,Healy Patrick,Alumkal Joshi J.,Winters Carolyn,Kephart Julie,Bitting Rhonda L.,Hobbs Carey,Soleau Colleen F.,Beer Tomasz M.,Slottke Rachel,Mundy Kelly,Yu Evan Y.,George Daniel J.

Funder

Novartis

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference30 articles.

1. Enzalutamide in metastatic prostate cancer before chemotherapy;Beer;N Engl J Med,2014

2. Sipuleucel-T immunotherapy for castration-resistant prostate cancer;Kantoff;N Engl J Med,2010

3. Abiraterone in metastatic prostate cancer without previous chemotherapy;Ryan;N Engl J Med,2013

4. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial;de Bono;Lancet,2010

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GPCR-Gα13 Involvement in Mitochondrial Function, Oxidative Stress, and Prostate Cancer;International Journal of Molecular Sciences;2024-06-28

2. Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers;International Journal of Molecular Sciences;2024-02-06

3. Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis;Molecular Oncology;2024-01-15

4. Resistance of prostate cancer to kinase inhibitors;Therapy Resistance in Prostate Cancer;2024

5. Exploring the role of PI3K/AKT/mTOR inhibitors in hormone-related cancers: A focus on breast and prostate cancer;Biomedicine & Pharmacotherapy;2023-12